MariMed (OTCMKTS:MRMD – Get Free Report) is expected to be releasing its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect MariMed to announce earnings of ($0.01) per share and revenue of $41.20 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.
MariMed (OTCMKTS:MRMD – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01). The company had revenue of $41.92 million during the quarter, compared to analysts’ expectations of $39.80 million. MariMed had a negative net margin of 9.13% and a negative return on equity of 10.71%.
MariMed Stock Down 2.0%
Shares of OTCMKTS:MRMD opened at $0.05 on Wednesday. The company has a quick ratio of 0.34, a current ratio of 0.92 and a debt-to-equity ratio of 1.78. The stock’s 50-day moving average is $0.07 and its 200-day moving average is $0.07. MariMed has a 52-week low of $0.04 and a 52-week high of $0.16.
MariMed Company Profile
MariMed, Inc is a U.S.-based cannabis company that develops, operates and manages licensed cannabis cultivation, processing and dispensary facilities. The company serves both medical and adult-use markets, where permitted by state law, and focuses on producing and distributing cannabis flower, concentrates, edibles, tinctures and other cannabis-infused products.
MariMed markets products under brands that have included Betty’s Eddies, Nature’s Heritage, InHouse and Kalm Fusion. Its products are sold through the company’s retail operations and third-party dispensaries in its operating markets.
Further Reading
- Five stocks we like better than MariMed
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.
